Annual Report 2014 Active Biotech AB (publ)

(Thomson Reuters ONE) -



Active Biotech's Annual Report 2014 is now available for download at
www.activebiotech.com.

The Annual Report will only be digitally distributed.


Lund, April 30, 2015
Active Biotech AB (publ)

Tomas Leanderson
President & CEO



For further information, please contact:
Hans Kolam
CFO
Tel +46 (0)46 19 20 44


Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal phase III development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in phase II development for the
treatment of primary progressive multiple sclerosis and Huntington's disease.
The project portfolio includes a preclinical project, ISI, with the objective to
produce new, patentable chemical compounds for treatment of diseases within the
company's focus areas. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 10:00 a.m. CET on April 30, 2015.

Annual Report 2014 Active Biotech AB (publ):
http://hugin.info/1002/R/1916577/685362.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.

Source: Active Biotech via GlobeNewswire
[HUG#1916577]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 30.04.2015 - 10:01 Uhr
Sprache: Deutsch
News-ID 389734
Anzahl Zeichen: 2249

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 152 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Annual Report 2014 Active Biotech AB (publ)"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech